Rethinking Clinical Trials
JANUARY 22, 2024
What happens to a pragmatic trial intervention after the study ends? In a new article from the NIH Pragmatic Trials Collaboratory, investigators from 6 of the program's completed pragmatic clinical trials summarize the posttrial interpretation of their trials' results and consider the factors that influenced the sustainment or de-implementation of the studies' interventions.
pharmaphorum
JANUARY 23, 2024
Bringing clinical trials to patients has become easier with the advent of digital technologies and decentralised clinical trials (DCTs). Learn how the hybrid approach combining traditional and digital methods can benefit patients and advance medical research.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
JANUARY 22, 2024
An online portal enabling people worldwide to find and express interest in clinical trials has been launched by Clinical Trial Media, a clinical trial participant recruitment and retention company.
WCG Clinical
JANUARY 24, 2024
basicsArentSoBasicWhitepaper Download The post The Basics Aren’t So Basic: Successful Participant Recruitment Requires Dedicated Time, Better Relationships, and Adequate Site Support appeared first on WCG.
Antidote
JANUARY 25, 2024
Recruiting patients for clinical trials is a common challenge for study sponsors conducting research. For this reason, it is often a wise strategy to work with an agency that specializes in outreach. These agencies excel at helping sponsors achieve their research goals within defined timelines and budgets.
Outsourcing Pharma
JANUARY 24, 2024
Sepehr Shojaei serves as the vice president of design solutions at Lightship, using his 15 years of experience in clinical research operations to champion a patient-centric approach.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 23, 2024
The National Institutes of Pharmaceutical Education and Research (NIPERs) can consider their own in-house scientists for the new faculty positions or recruit pharmaceutical industry professionals for the Professor of Practice positions in the absence of suitable applications for faculty positions, recommends a study by the Department of Pharmaceuticals (DoP).
Rethinking Clinical Trials
JANUARY 24, 2024
In this Friday's PCT Grand Rounds, Suresh Balu and Marc Sendak of Duke University will present "Advancing the Safe, Effective, and Equitable Use of AI in Healthcare." The Grand Rounds session will be held on Friday, January 26, 2024, at 1:00 pm eastern. Balu is the director of the Duke Institute for Health Innovation (DIHI) and the associate dean for innovation and partnership in the Duke University School of Medicine.
Bio Pharma Dive
JANUARY 24, 2024
An 11-year-old boy born deaf can hear after receiving Lilly's genetic medicine. Others, including biotechs in China and Regeneron in the U.S., are taking aim at the same drug target.
Pharmaceutical Technology
JANUARY 21, 2024
CDMOs, who cater to the requirements of multiple companies and develop platform processes to achieve the much-needed economy of scale, are being seen as a possible solution.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 24, 2024
According to Greek mythology, Zeus punished Prometheus for giving fire to humans. He chained Prometheus up and set an eagle to feast on his liver. Each night, the liver grew back and each day, the eagle returned for his feast. In reality, can a liver really grow back?
Rethinking Clinical Trials
JANUARY 23, 2024
Ethics and regulatory onboarding documentation is now available for RAMP, one of the NIH Pragmatic Trials Collaboratory's newest pragmatic clinical trials. The documents include meeting minutes and supplementary materials summarizing recent discussions of ethics and regulatory issues associated with the study. The consultation took place by video conference and included representation from the study's principal investigator and study team, members of the NIH Collaboratory's Ethics and Regulatory
Bio Pharma Dive
JANUARY 22, 2024
New details of the proposed acquisitions show there were multiple interested buyers, which, according to some analysts, could set the stage for more dealmaking.
Pharmaceutical Technology
JANUARY 22, 2024
On 18 January 2024, US-based biotech CG Oncology announced it was looking to raise $200m in an upcoming initial public offering (IPO), which will be the first for the biotech sector in 2024.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 23, 2024
Wegovy, Ozempic and Mounjaro are weight loss and diabetes drugs that have made quite a splash in health news. They target regulatory pathways involved in both obesity and diabetes and are widely considered breakthroughs for weight loss and blood sugar control. [link] But do these drugs point toward a root cause of metabolic disease?
Fierce Pharma
JANUARY 26, 2024
Merck’s unique approval for Keytruda as a postsurgical treatment for resectable kidney cancer has gained new backing in the form of data showing the PD-1 inhibitor can extend patients’ lives. | Merck’s unique approval for Keytruda as a postsurgerical treatment for resectable kidney cancer has gained new backing in the form of data showing the PD-1 inhibitor can extend patients’ lives.
Bio Pharma Dive
JANUARY 26, 2024
The opinion would allow Abecma to be prescribed after two standard therapies and is the latest sign of CAR-T’s growing use in earlier cancer treatment.
Pharmaceutical Technology
JANUARY 24, 2024
Accent Therapeutics has raised $75m in a Series C financing round to progress the development of precision cancer therapies.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 22, 2024
Neuroscientists at Washington State University think they have figured out why cannabis is so notorious for causing the ‘munchies’ among users. Their research on mice is the first to investigate how cannabis impacts the real-time activity of brain regions that control appetite.
Fierce Pharma
JANUARY 22, 2024
As many have feared, the FDA’s investigation into secondary T-cell cancers following treatment with existing CAR-T therapies is poised to lead to a classwide black box warning. | As many have feared, the FDA's investigation into secondary T-cell malignancies following treatment with existing CAR-T therapies is poised to lead to a classwide black box warning.
Bio Pharma Dive
JANUARY 22, 2024
Trodelvy didn’t outperform chemotherapy in a large study of people with a common lung tumor, a setback that sent company shares down by double digits.
Pharmaceutical Technology
JANUARY 26, 2024
CAR-T cell therapies can provide durable cancer remission, however, a recent FDA investigation into reports of secondary T-cell malignancies has increased scrutiny of their risk profiles.
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 21, 2024
With a fatality rate 20 times that of COVID-19, and no vaccine, Disease X could swiftly bring humanity to its knees. Few would be left untouched by the pathogen were it to gain hold, causing healthcare systems to crumble and economies to collapse as the world once again tried to contain a force of nature.
Antidote
JANUARY 26, 2024
Colorectal cancer (often shortened simply to colon cancer) is the fourth-most commonly diagnosed cancer in the United States, and it is estimated that around 150,000 Americans are diagnosed each year. While the average age of diagnosis is 66, young adults are getting diagnosed in higher numbers every year, and researchers are still unsure as to why.
Bio Pharma Dive
JANUARY 23, 2024
A black box warning for secondary T cell malignancies should be added to the labeling of all six approved CAR-T therapies, the agency said.
Pharmaceutical Technology
JANUARY 22, 2024
The UK NICE recommends Pfizer's talazoparib, marketed as Talzenna, to treat a specific type of locally advanced or metastatic breast cancer.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 25, 2024
The Central government’s actions to mandate licensing of all medical devices is posing a challenge to the industry, especially the micro and small enterprises in the sector, says the Surgical Manufacturers and Traders Association (SMTA), the pan India organisation of manufacturers and traders of surgical equipment for healthcare services providers in the country.
XTalks
JANUARY 26, 2024
World Cancer Day 2024 is a global initiative that emphasizes the importance of heightened awareness about cancer. This day is observed annually on February 4th since its inception by the Union for International Cancer Control (UICC) in 2000. World Cancer Day is dedicated to encouraging early detection, prevention and treatment while also advocating for improved access to healthcare services for those affected by cancer.
Bio Pharma Dive
JANUARY 24, 2024
The sector’s first IPO of 2024 could be positive signal for the handful of other companies that have recently laid out plans for initial public offerings.
Pharmaceutical Technology
JANUARY 24, 2024
The company could be in line for a priority review voucher if 4D-710, currently in Phase I/II clinical trials, is approved.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
162 
Let's personalize your content